Ping An Healthcare and Technology Company Limited (HKG:1833) Just Reported, And Analysts Assigned A HK$16.50 Price Target
Ping An Healthcare and Technology Company Limited (HKG:1833) Just Reported, And Analysts Assigned A HK$16.50 Price Target
Last week, you might have seen that Ping An Healthcare and Technology Company Limited (HKG:1833) released its interim result to the market. The early response was not positive, with shares down 8.9% to HK$10.00 in the past week. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
上週,您可能已經看到中國平安健康科技股份有限公司(SEHK:1833)發佈了其半年報。 早期的反應並不積極,過去一週,股價下跌8.9%至10.00港元。 在此結果公佈後,分析師已更新了其盈利模型,很好知道他們是否認爲公司前景發生了重大變化,或者是否一切如常。 爲此,我們收集了最新的法定預測,以查看分析師對明年的預期。
![1724365165469](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240823/42758480-0-befebb9ad96d5513e2f94d1b5f9498e5.webp/bigjpg)
Following last week's earnings report, Ping An Healthcare and Technology's twelve analysts are forecasting 2024 revenues to be CN¥4.55b, approximately in line with the last 12 months. Earnings are expected to improve, with Ping An Healthcare and Technology forecast to report a statutory profit of CN¥0.093 per share. Before this latest report, the consensus had been expecting revenues of CN¥5.26b and CN¥0.14 per share in losses. So it's pretty clear that although the analysts have made a substantial drop in to their revenue estimates, the business is expected to reach profitability earlier, after the latest results.
在上週的業績發佈後,中國平安健康科技的十二位分析師預測2024年營業收入將達到45.5億元,與過去12個月基本持平。 預計盈利將有所改善,中國平安健康科技預計將報告每股盈利0.093元。在最新業績發佈之前,市場預期收入爲52.6億元,每股虧損爲0.14元。 因此,顯然,儘管分析師對其收入估計有大幅下調,但該企業預計將在最新業績後較早實現盈利。
The analysts have cut their price target 6.2% to HK$16.50per share, suggesting that the declining revenue was a more crucial indicator than the expected improvement in earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Ping An Healthcare and Technology at HK$35.14 per share, while the most bearish prices it at HK$10.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
分析師將其股價目標下調了6.2%,至16.50港元/股,這表明收入下降比預期的盈利改善更爲關鍵。然而,只關注單一的股價目標可能不明智,因爲共識目標其實是分析師目標的平均值。因此,一些投資者喜歡查看估計範圍,以查看對企業估值是否存在分歧意見。目前,最看好的分析師將中國平安健康科技股票的估值定爲35.14港元/股,而最看淡的估值爲10.00港元/股。鑑於股價目標的如此大範圍,分析師幾乎肯定是在對企業的基本業務產生了各不相同的結果。因此,我們不會過於依賴共識股價目標,因爲它只是一個平均值,並且分析師對企業的看法明顯存在深刻分歧。
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's also worth noting that the years of declining revenue look to have come to an end, with the forecast stauing flat to the end of 2024. Historically, Ping An Healthcare and Technology's top line has shrunk approximately 1.5% annually over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 10% annually. Although Ping An Healthcare and Technology's revenues are expected to improve, it seems that it is still expected to grow slower than the wider industry.
現在來看看更大的畫面,了解這些預測的一種方式是看它們與過去的表現和行業增長預期的比較。值得注意的是,下降的營業收入年份似乎已經結束,預測顯示到2024年底將保持平穩。根據歷史數據,中國平安健康科技的營業收入在過去五年中每年大約下降1.5%。將此與整個行業的分析師預測進行比較,整體上行業收入預計每年增長10%。儘管預計中國平安健康科技的營業收入將有所改善,但似乎仍預計增速略慢於更廣泛的行業。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that there's been a clear step-change in belief around the business' prospects, with the analysts now expecting Ping An Healthcare and Technology to become profitable next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Still, earnings per share are more important to value creation for shareholders. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
最重要的是,人們明顯改變了對業務前景的信念,分析師現在預計中國平安健康科技明年能夠盈利。不幸的是,他們還下調了營業收入的預期,我們的數據顯示業績低於更廣泛的行業。儘管如此,每股收益對業務的內在價值更爲重要。此外,每股收益對股東的價值創造更爲重要。此外,分析師還下調了其價格目標,這表明最新的資訊導致對業務內在價值更大的悲觀情緒。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Ping An Healthcare and Technology analysts - going out to 2026, and you can see them free on our platform here.
記住,對於投資者來說,業務的長期軌跡更爲重要。我們有來自多位中國平安健康科技分析師的估算,延伸至2026年,你可以在我們的平台上免費查看。
You can also see our analysis of Ping An Healthcare and Technology's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
您還可以看到我們對中國平安健康科技董事會和首席執行官薪酬和經驗的分析,以及公司內部人員是否一直在買入股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。